One‐time administration of these vectors to obese animals enabled a long‐lasting increase in FGF21 levels in circulation, which resulted in sustained counteraction of obesity, adipose tissue inflammation, insulin resistance, and NASH in the absence of adverse events. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.